RNAi therapeutic for transthyretin mediated amyloidosis (Arcturus Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameRNAi therapeutic for transthyretin mediated amyloidosis (Arcturus Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionTransthyretin modulators
TargetsTransthyretin
Therapy Area/IndicationsAmyloid Neuropathies, Familial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArcturus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArcturus Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAmyloid Neuropathies, Familial

Other Information

ATC CodeN/A
Related LinksN/A